Journal of Medicinal Chemistry

Journal of Medicinal Chemistry
source
Title	Journal of Medicinal Chemistry
Discipline	Medicinal chemistry
Abbreviation	J. Med. Chem.
Publisher	American Chemical Society
Country	United States
History	1959–present
Frequency	Biweekly
Issn	0022-2623

Contents

Journal of Medicinal Chemistry is a peer-reviewed scientific journal published by the American Chemical Society covering research in drug discovery and design. Founded in 1959 during a period of expansion in pharmaceutical research associated with institutions such as Merck & Co., Pfizer, GlaxoSmithKline, the journal has become a central venue alongside publications like Nature Reviews Drug Discovery and The Lancet for reporting advances that intersect with organizations such as National Institutes of Health, World Health Organization, and laboratories at Harvard University and Stanford University.

History

The journal was established in 1959 amid postwar growth tied to companies including Eli Lilly and Company, Johnson & Johnson, and academic centers like Massachusetts Institute of Technology and University of Cambridge. Early editors collaborated with societies such as the American Chemical Society and interacted with regulatory agencies including the Food and Drug Administration and the European Medicines Agency. Over decades the journal mirrored shifts driven by milestones like the advent of high-throughput screening, the rise of biotechnology exemplified by Genentech, and the sequencing efforts of the Human Genome Project, while publishing work from researchers affiliated with Columbia University, Oxford University, University of California, San Francisco, and corporate labs at Bayer and Roche.

The journal focuses on medicinal chemistry topics that connect to drug targets studied at institutions such as National Cancer Institute, Scripps Research Institute, and Cold Spring Harbor Laboratory. Authors report synthetic chemistry often linked to efforts at Bristol-Myers Squibb and AstraZeneca, structure–activity relationships relevant to teams at Novartis and Amgen, and computational studies influenced by methods from Bell Labs and Los Alamos National Laboratory. Coverage includes small-molecule design informed by structural biology work from European Molecular Biology Laboratory, pharmacokinetics studied in collaborations with Johns Hopkins University, and chemical biology approaches used at California Institute of Technology and Yale University.

The journal is produced biweekly by the American Chemical Society with an editorial board drawn from faculty at University of Cambridge, Imperial College London, University of Tokyo, and industry scientists from Pfizer and Merck & Co.. Peer review processes mirror standards in journals such as Journal of the American Chemical Society and Angewandte Chemie, with submissions managed through systems used by publishers including Wiley and Springer Nature. The journal publishes original research articles, reviews, and perspectives authored by investigators at centers like University of Pennsylvania, UCSF, and ETH Zurich.

The journal is indexed in major services alongside titles like Science, Cell, and Proceedings of the National Academy of Sciences: databases include PubMed, Scopus, and Web of Science. It is discoverable through library consortia such as OCLC and cataloged in collections used by institutions like Princeton University Library and Harvard Library. Abstracting services that index the journal often serve researchers at MIT, Caltech, and Indian Institute of Science.

The journal is widely cited by authors associated with research at National Institutes of Health, Centers for Disease Control and Prevention, and leading universities including Stanford University and University of Oxford. Its articles have influenced drug approvals reviewed by the Food and Drug Administration and the European Medicines Agency and informed programs at companies such as Novartis and Gilead Sciences. It is commonly ranked in comparison with titles like Chemistry—A European Journal and ACS Chemical Biology in bibliometric analyses performed by groups at Clarivate and Elsevier.

Seminal papers published in the journal originated from laboratories led by investigators connected to Salk Institute, Cold Spring Harbor Laboratory, Rockefeller University, and pharmaceutical teams at Eli Lilly and Company and Roche. Contributions include structure–activity relationship studies that underpinned drugs developed at GlaxoSmithKline and AstraZeneca, computational methods adopted in collaborations with IBM Research and Google DeepMind, and medicinal chemistry strategies applied in programs at Amgen and Bristol-Myers Squibb. Review articles and perspectives have been authored by scientists affiliated with Yale University, University of Chicago, and McGill University, influencing subsequent work on targets studied at Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center.

Category:Medicinal chemistry journals Category:American Chemical Society journals